| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Copyright/Subscription
|
|
|
2013
|
16 |
6S |
p. iv-
1 p.
|
artikel
|
| 2 |
Current Methodological Issues in the Economic Assessment of Personalized Medicine
|
Annemans, Lieven
|
|
2013
|
16 |
6S |
p. S20-S26
7 p.
|
artikel
|
| 3 |
Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine
|
Towse, Adrian
|
|
2013
|
16 |
6S |
p. S39-S43
5 p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
2013
|
16 |
6S |
p. IFC-
1 p.
|
artikel
|
| 5 |
Instructions for Authors
|
|
|
2013
|
16 |
6S |
p. I-II
nvt p.
|
artikel
|
| 6 |
Melding Regulatory, Pharmaceutical Industry, and U.S. Payer Perspectives on Improving Approaches to Heterogeneity of Treatment Effect in Research and Practice
|
Willke, Richard J.
|
|
2013
|
16 |
6S |
p. S10-S15
6 p.
|
artikel
|
| 7 |
Personalized Medicine and the Role of Health Economics and Outcomes Research: Issues, Applications, Emerging Trends, and Future Research
|
O’Donnell, John C.
|
|
2013
|
16 |
6S |
p. S1-S3
3 p.
|
artikel
|
| 8 |
Reflections on Market Access for Personalized Medicine: Recommendations for Europe
|
Payne, Katherine
|
|
2013
|
16 |
6S |
p. S32-S38
7 p.
|
artikel
|
| 9 |
Regulation, Reimbursement, and the Long Road of Implementation of Personalized Medicine—A Perspective from the United States
|
Frueh, Felix W.
|
|
2013
|
16 |
6S |
p. S27-S31
5 p.
|
artikel
|
| 10 |
Table of Contents
|
|
|
2013
|
16 |
6S |
p. iii-
1 p.
|
artikel
|
| 11 |
The Faces of Personalized Medicine: A Framework for Understanding Its Meaning and Scope
|
Redekop, W. Ken
|
|
2013
|
16 |
6S |
p. S4-S9
6 p.
|
artikel
|
| 12 |
Title Page
|
|
|
2013
|
16 |
6S |
p. i-
1 p.
|
artikel
|
| 13 |
Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use
|
Burns, Leah C.
|
|
2013
|
16 |
6S |
p. S16-S19
4 p.
|
artikel
|
Tijdschrift beschrijving